Bpifrance led a $75m Series B round in TreeFrog Therapeutics.

Bpifrance led a $75m Series B round in TreeFrog Therapeutics, a privately held French-based biotech startup, with participation from Leonard Green & Partners, Bristol Myers Squibb and XAnge. The latest funding round will be used to deploy biomimetic C-StemTM technology for clinical-grade manufacturing, grow and advance to the clinic a comprehensive pipeline of cell therapies, and finance the opening of technological hubs in Boston, MA, and Kobe, Japan.